A61K 40/412
Contraceptive or sex hormones
Official title: {Contraceptive or sex hormones}
A61K40/412 (Contraceptive or sex hormones) appears on 9 US grants and 14 published applications in this corpus.
Search patents in A61K- Granted patents
- 9
- Published applications
- 14
- Assignees
- 7
- Inventors
- 20
- Latest grant
- 14 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 0 | 2 |
| 2021 | 1 | 0 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 1 | 2 |
| 2025 | 3 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Gene fusions for control of genetically modified cells14 Apr 2026US 12,599,665 B2A2 Biotherapeutics, Inc.
- Cell therapy for patients4 Nov 2025US 12,458,249 B2
- Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells13 May 2025US 12,295,973 B2Fred Hutchinson Cancer Center
- Compositions and methods for immunotherapy15 Apr 2025US 12,275,802 B2Memorial Sloan Kettering Cancer Center
- Method of producing a peripheral blood mononuclear cell composition suitable for repairing or engineering a tissue16 Apr 2024US 11,957,384 B2Progena Inc.
- Cell therapy for patients12 Feb 2026US 2026/0041337 A1
- Compositions and methods for immunotherapy28 Aug 2025US 2025/0270347 A1Memorial Sloan Kettering Cancer Center
- Method of producing a peripheral blood mononuclear cell composition suitable for repairing or engineering a tissue15 Aug 2024US 2024/0268863 A1Progena Inc.
- Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells21 Mar 2024US 2024/0091265 A1Fred Hutchinson Cancer Center
- Gene fusions for control of genetically modified cells19 Oct 2023US 2023/0330227 A1A2 Biotherapeutics, Inc.
Most cited
By later US patents